BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura

References

• Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: A tutorial on B-cell survival. Annu Rev Immunol 2003; 21: 231–264
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B-cell growth. J Exp Med 1999; 189: 1747–1756
   PubMed Web of Science ®Google Scholar
• Karpusas M, Cachero TG, Qian F, Boriack-Sjodin A, Mullen C, Strauch K, Hsu YM, Kalled SL. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 2002; 315: 1145–1154
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM. BAFF-R, the major B-cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 2005; 36: 1113–1119
   Google Scholar
• Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111–2114
   PubMed Web of Science ®Google Scholar
• Mackay F, Browning JL. BAFF: A fundamental survival factor for B cells. Nat Rev Immunol 2002; 2: 465–475
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785–798
   PubMed Web of Science ®Google Scholar
• Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441–453
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697–1710
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995–1008
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol 2005; 54: 107–116
   PubMed Web of Science ®Google Scholar
• Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, Maniatis A, Mouzaki A. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004; 103: 2645–2647
   PubMed Web of Science ®Google Scholar
• Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, Han ZC. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005; 90: 914–923
   PubMed Web of Science ®Google Scholar
• Siegel RM, Lenardo MJ. To B or not to B: TNF family signaling in lymphocytes. Nat Immunol 2001; 2: 577–578
   Google Scholar
• Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313–1319
   PubMed Web of Science ®Google Scholar
• Mackay IR, Groom J, Mackay CR. Levels of BAFF in serum in primary biliary cirrhosis andautoimmune diabetes. Autoimmunity 2002; 35: 551–553
   PubMed Web of Science ®Google Scholar
• Emmerich F, Bal G, Barakat A, Milz J, Muhle C, Martinez-Gamboa L, Dorner T, Salama A. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007; 136: 309–314
   PubMed Web of Science ®Google Scholar
• Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002; 168: 3675–3682
   PubMed Web of Science ®Google Scholar
• Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006; 15: 570–576
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005; 25: 298–302
   PubMed Web of Science ®Google Scholar
• Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003; 62: 168–171
   PubMed Web of Science ®Google Scholar
• Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005; 25: 189–201
   PubMed Web of Science ®Google Scholar
• Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P. BAFFoverexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34–39
   PubMed Web of Science ®Google Scholar
• Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6–10
   PubMed Web of Science ®Google Scholar
• Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol 2006; 63: 299–303
   Google Scholar
• Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFFlevels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192–201
   PubMed Web of Science ®Google Scholar
• Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmstrom P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 2004; 152: 183–190
   PubMed Web of Science ®Google Scholar
• Huard B, Arlettaz L, Ambrose C, Kindler V, Mauri D, Roosnek E, Tschopp J, Schneider P, French LE. BAFF production by antigen-presenting cells provides T-cell co-stimulation. Int Immunol 2004; 16: 467–475
   PubMedGoogle Scholar
• Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS. TACI-ligand interactions are required for T-cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2: 632–637
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang L, Wells AD, Tao R, Han R, Davidson A, Scott ML, Hancock WW. BAFF binding to T-cell-expressed BAFF-R costimulates T-cell proliferation and alloresponses. Eur J Immunol 2004; 34: 2750–2759
   PubMedGoogle Scholar
• Sutherland AP, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, Rolph MS, Mackay F, Mackay CR. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005; 174: 5537–5544
   PubMed Web of Science ®Google Scholar
• Mackay F, Leung H. The role of the BAFF/APRIL system on T-cell function. Semin Immunol 2006; 18: 284–289
   PubMed Web of Science ®Google Scholar
• Huntington ND, Tomioka R, Clavarino C, Chow AM, Linares D, Mana P, Rossjohn J, Cachero TG, Qian F, Kalled SL, Bernard CC, Reid HH. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 2006; 18: 1473–1485
   PubMed Web of Science ®Google Scholar
• Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C, Gestermann N, Proust A, Lambotte O, Mariette X. Decreased B-cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 790–797
   PubMed Web of Science ®Google Scholar
• Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y. Expression of B-cell activating factor of thetumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: The role of BAFF in T-cell-dependent B-cell pathogenic autoantibody production. Rheumatology (Oxford) 2007; 46: 1083–1086
   PubMed Web of Science ®Google Scholar
• Ju S, Zhang D, Wang Y, Ni H, Kong X, Zhong R. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006; 39: 1131–1137
   PubMed Web of Science ®Google Scholar
• Carter RH, Zhao H, Liu X, Pelletier M, Chatham W, Kimberly R, Zhou T. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3943–3954
   PubMed Web of Science ®Google Scholar
• Provan D, Newland AC, Norfolk D, Bolton-Maggs P, Lilleyman J, Greer I, May A, Murphy M, Ouwehand W, Watson S. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574–596
   PubMed Web of Science ®Google Scholar
• Wang T, Xu M, Ji L, Han ZC, Yang R. Splenectomy for adult chronic idiopathic thrombocytopenic purpura: Experience from a single center in China. Eur J Haematol 2005; 75: 424–429
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623–2634
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F. Association of BAFF/BLyS overexpression and altered B-cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109: 59–68
   PubMed Web of Science ®Google Scholar
• Zhou Z, Yang R. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Crit Rev Oncol Hematol 2008; 65: 21–31
   PubMed Web of Science ®Google Scholar